Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
- Conditions
- MCA - Middle Cerebral Artery Dissection
- Registration Number
- NCT02953405
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Brief Summary
Prescription and Persistence of Antithrombotic agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients with MCA(Middle Cerebral Artery) Disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- 19 years later, men and women
Exclusion Criteria
- Subject who is judged to be ineligible by investigator
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prescription status of Antithrombotic Agents at 12 months after baseline(onset)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antithrombotic efficacy in MCA dissection post-stroke patients?
How do antithrombotic regimens compare in preventing recurrent stroke in MCA disease vs. standard care?
Which biomarkers predict adherence to antithrombotic therapy in MCA dissection patients?
What adverse event profiles are associated with long-term antithrombotic use in MCA stroke survivors?
Are combination therapies with DOACs and antiplatelet agents being explored for MCA dissection management?
Trial Locations
- Locations (1)
SNUBH
🇰🇷Seoul, Korea, Republic of
SNUBH🇰🇷Seoul, Korea, Republic of